Literature DB >> 12132530

Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phosphokinase, severe muscle symptoms and positive anti-Jo-1 antibody.

Kosuke Kashiwabara1, Kosuke Ota.   

Abstract

It has been reported that there is a subgroup of dermatomyositis (DM) patients with rapidly progressive interstitial lung disease (ILD) who have mild muscle symptoms, slightly increased levels of muscle enzymes, and absence of anti-Jo-1 antibody. A 51-year-old woman with DM was intubated requiring mechanical ventilation because of a rapidly progressing ILD in spite of the absence of the typical poor prognostic factors. A high dose or pulse therapy of corticosteroids was not effective, but additional treatment of cyclosporine gradually improved her respiratory condition. It is not clear why a rapidly progressive ILD occurred in this case lacking poor prognostic factors. However, if corticosteroid treatment is not effective, additional administration of cyclosporine in the early period of rapidly progressive ILD may rescue deteriorating cases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12132530     DOI: 10.2169/internalmedicine.41.584

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Report of a Patient With Anti-Jo-1 Syndrome With Loss of Consciousness.

Authors:  Chun Chen; Yu-Jang Su; Chiong-Hee Wong
Journal:  J Acute Med       Date:  2022-06-01

2.  Antisynthetase syndrome (ASS) presenting as acute respiratory distress syndrome (ARDS) in a patient without myositis features.

Authors:  Venkat Kiran Kanchustambham; Swetha Saladi; Sarah Mahmoudassaf; Setu Patolia
Journal:  BMJ Case Rep       Date:  2016-12-09

3.  Severe juvenile dermatomyositis: two patients complicated with extra musculocutaneous involvement.

Authors:  Ayşe Tosun; Gül Serdaroğlu; Mehmet Tayyip Aslan; Muzaffer Polat; Taner Akalin; Hasan Tekgul; Sarenur Gökben
Journal:  Rheumatol Int       Date:  2006-05-24       Impact factor: 2.631

4.  Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease.

Authors:  Soran Peshbahar; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2020-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.